Other languages Daré Bioscience, Inc.

Equities

DARE

US23666P1012

Real-time Estimate Cboe BZX Other stock markets 07:38:27 18/06/2024 pm IST			5-day change	1st Jan Change
0.432 ^USD	-0.67%		-7.25%	+39.16%

15/05	Brookline Capital Upgrades Dare Bioscience to Buy From Hold, Price Target is $3	MT
14/05	Transcript : Daré Bioscience, Inc., Q1 2024 Earnings Call, May 14, 2024

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Daré Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05
Daré Bioscience, Inc. Closes Royalty Monetization Transaction with XOMA (US) LLC	30/04
XOMA Corporation completed the acquisition of three First-in-Category Assets of Daré Bioscience, Inc. for $22 million.	30/04
Daré Bioscience, Inc. Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1	23/04
Daré Bioscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/03
Daré Bioscience, Inc. Announces Positive End-Of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024	31/01
Daré Bioscience, Inc. Announces Executive Changes	27/01
Dare Bioscience Says Chief Financial Officer Retiring, Chief Commercial Officer Has Resigned	27/01
Dare Bioscience, Inc. Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the Dare-Pdm1 Phase 1 Clinical Study	20/12
Dare Bioscience Obtains FDA Clearance for Phase 2 Trial of Potential Dyspareunia Treatment	07/12
Dare Bioscience, Inc. Announces FDA Clearance of Investigational New Drug Application for DARE-VVA1	07/12
Dare Bioscience, Inc. Announces Commencement of Phase 3 Study of Ovaprene, an Investigational Hormone-Free Monthly Intravaginal Contraceptive	04/12
Dare Bioscience Extends Agreement With Premier Research to Advance Reproductive Health Portfolio	20/11
Dar Bioscience, Inc. and Premier Research International LLC Extend Strategic Partnership to Accelerate the Clinical Development of Dar's Novel Women's Health Programs	20/11
Daré Bioscience, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2023	09/11
Dare Bioscience Says Additional Data Show Sildenafil Cream Improving Sexual Disorder Symptoms	01/11
Sector Update: Health Care Stocks Rise Late Afternoon	17/23/17
Sector Update: Health Care Stocks Gaining Monday Afternoon	16/23/16
Dare Bioscience Triggers $1.8 Million Milestone Payment from Organon With Xaciato's First Shipment	16/23/16
Dare Bioscience to Get $4.5 Million Grant Funding Installment for Development of Contraceptive Technology	21/23/21

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Daré Bioscience, Inc.

Equities

DARE

US23666P1012

Other languages

Filters